AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
(NASDAQ: ACIU) Delayed: 2.63 -0.05 (1.87%)
Previous Close $2.68    52 Week High $19.97 
Open $2.69    52 Week Low $10.36 
Day High $2.81    P/E N/A 
Day Low $2.63    EPS $0.00 
Volume 68,462